Journal article
An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients
Cancer immunology research, Vol.7(9), pp.1511-1522
09/01/2019
DOI: 10.1158/2326-6066.CIR-18-0821
PMCID: PMC6726511
PMID: 31383650
Abstract
Ligand-receptor complexes play a central role in mediating a range of processes in immunology and cancer biology. The ability to directly quantify the fraction of receptors occupied by a ligand in a given biospecimen, as opposed to assessing the concentration of ligand and receptor separately, could provide an additional and valuable clinical and research tool for assessing whether receptors are occupied by a ligand. To address this need, a biomarker platform was developed to quantify the fraction of receptors occupied by a ligand using pairs of RNA aptamers, where one aptamer binds preferentially to the unoccupied receptor and the other to the ligand-receptor complex. Bound aptamer was quantified using RT-qPCR colorimetric probes specific for each aptamer. The binding ratio of aptamer correlated with the fraction of receptors occupied by a ligand. This assay, termed as LIRECAP (LIgand-REceptor Complex-binding APtamer) assay, was used to determine the fraction of soluble CD25 occupied by IL2 in the serum from subjects with B-cell lymphoma. No correlation was found between the type of lymphoma and total soluble CD25 or IL2 independently. In contrast, the fraction of soluble CD25 occupied by IL2 was significantly higher in follicular lymphoma patient serum compared with diffuse large B-cell lymphoma patient serum. We conclude that this technology has the potential to serve as a high-throughput biomarker platform to quantify the fraction of receptors occupied by a ligand.
Details
- Title: Subtitle
- An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients
- Creators
- Suresh Veeramani - HoldenSue E. Blackwell - University of IowaWilliam H. Thiel - University of IowaZhi-Zhang Yang - Mayo Clinic , Rochester, Minnesota.Stephen M. Ansell - Mayo ClinicPaloma H. Giangrande - University of IowaGeorge J. Weiner - Holden
- Resource Type
- Journal article
- Publication Details
- Cancer immunology research, Vol.7(9), pp.1511-1522
- DOI
- 10.1158/2326-6066.CIR-18-0821
- PMID
- 31383650
- PMCID
- PMC6726511
- NLM abbreviation
- Cancer Immunol Res
- ISSN
- 2326-6066
- eISSN
- 2326-6074
- Publisher
- Amer Assoc Cancer Research
- Number of pages
- 12
- Grant note
- P50CA097274 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) P30 CA86862; P50 CA97274 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA P30ES005605 / NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
- Language
- English
- Date published
- 09/01/2019
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Cardiovascular Medicine; Radiation Oncology; Holden Comprehensive Cancer Center; Internal Medicine
- Record Identifier
- 9984359839802771
Metrics
23 Record Views